Salvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncology

Background: We aimed to evaluate prognostic factors and response rates to various treatment approaches topatients with synovial sarcoma in an advanced setting. Materials and
Methods: We retrospectively reviewed themedical records of 55 patients (18 pts; 32.7% women) diagnosed with synovial sarcomas. Twenty had metastaticdisease at the time of diagnosis while the remainder of the study group consisted of patients who developedmetastatic or inoperable locally advanced disease during follow up.
Results: The median follow up time was 15months (range: 1-53). Regarding outcomes for the 55 patients, 3 and 5 year overall survival rates were 26% and14%, respectively. In univariate analyses among demographic factors female gender was associated with a betteroutcome (p=0.030). Patients with early progressing disease (<2 years) had a worse prognosis when comparedto patient group with late relapse, but this difference did not reach statistical significance (p=0.056). Accordingto multivariate Cox regression analysis patients who had undergone metastasectomy had a significant survivaladvantage (p=0.044). The overall response rate to different salvage chemotherapy regimens given as second linetreatment was around 42.9-53.9% for all regimes. There were no statistically significant differences betweenchemotherapy regimens given in either second or third line settings in terms of overall survival.
Conclusions: Weobserved no major differences in terms of response rate and survival between different salvage chemotherapyregimens. Although metastatic disease still carries a poor prognosis, metastasectomy was found to be associatedwith improved survival